Corynebacterium pseudotuberculosis gene deletion strain, vaccine and preparation method thereof
The CRISPR/Cas9 technology constructed a live vaccine that combines XH02ΔsodC with adjuvant gene deletion strain XH02ΔsodC with adjuvant, which solved the problems of high preparation cost and poor immune protection effect of existing vaccines, and achieved low-cost and efficient immune stimulation and infection Protective effect.
Patent Information
- Application Number
- CN202411228695.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-11-08
AI Technical Summary
The existing Rosy Bacillus pseudotuberculosis vaccine has the problems of high preparation cost, limited immune protection effect, poor immunogenicity and difficulty in stimulating humoral and cellular immunity. It also has low efficiency in traditional drugs and surgical treatments, and high risk of drug resistance and contamination.
CRISPR/Cas9 gene editing technology knocked out the copper-zinc superoxide dismutase gene of Corynebacterium pseudotuberculosis, constructed the gene deletion strain XH02ΔsodC, and combined it with Montanide™ Gel 02 adjuvant to prepare a live vaccine, and stimulate the immune response through low-dose vaccination. .
Achieving low-cost and simple vaccine preparation, significantly improving the humoral and cellular immunity levels of immune animals, effectively resisting Corynebacterium pseudotuberculosis infection, reducing pathogenicity and infection rate, and having a high immune protection rate, suitable for large-scale Production.
Smart Images

Figure BDA0005025441150000031 
Figure HDA0005025441160000011 
Figure HDA0005025441160000021
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of Corynebacterium pseudotuberculosis, and in particular relates to a Corynebacterium pseudotuberculosis gene-deficient strain, a vaccine and a preparation method thereof. Background Art
[0002] Corynebacterium pseudotuberculosis is a Gram-positive facultative intracellular parasitic bacterium that can cause chronic infectious diseases in a variety of animals such as sheep, cattle, horses, and humans, mainly causing suppuration and caseous necrosis of the body surface and internal organs. In animal clinical practice, Corynebacterium pseudotuberculosis is most common in goats and sheep. In recent years, Corynebacterium pseudotuberculosis has been very popular in goat farming in my country, including Shaanxi, Sichuan, Chongqing, Yunnan, Fujian and other provinces and cities have reported infection with the pathogen, and the isolation rate of the pathogen in the abscess samples of the diseased sheep is 39.22-100%. Corynebacterium pseudotuberculosis infection can cause the production performance of goats to decline, meat products and skins to be discarded, and the appearance of abscesses affects sales, etc., which seriously affects the economic benefits of the sheep farming industry.
[0003] At present, the main methods for preventing and controlling pseudotuberculosis in my country are drug treatment and surgical treatment, but neither can fundamentally limit the infection of the pathogen. Its shortcomings are reflected in:
[0004] The effect of drug control is not ideal. The reasons are as follows: (1) It is difficult for drugs to enter the abscess or caseous necrosis capsule caused by Corynebacterium pseudotuberculosis; (2) The large-scale use of drugs to control the disease is prone to pathogen resistance and drug residue problems. Surgical treatment is cumbersome, as shown in the following aspects: (1) Low efficiency, requiring each sick sheep to be examined and operated on; (2) The process of surgical incision and drainage of abscesses is likely to pollute the environment; (3) It can only treat abscesses on the surface of the body, but cannot treat abscesses in internal organs.
[0005] Vaccination is the most economical and efficient method to prevent and control the infection of Corynebacterium pseudotuberculosis. Existing Corynebacterium pseudotuberculosis vaccines are mainly studied based on strains isolated from clinical sites, but most of them are inactivated vaccines or subunit vaccines, which have high production costs. In addition, Corynebacterium pseudotuberculosis is a facultative intracellular parasite. Both cellular immunity and humoral immunity play an important role in responding to infection with this pathogen. However, the ability of inactivated vaccines to induce cellular immune responses is limited.
[0006] Existing Corynebacterium pseudotuberculosis toxin vaccines often have problems such as a single toxin type, difficulty in obtaining, and the need for inactivation with an inactivator. In addition, the immunogenicity is poor, the immune protection rate is relatively low, and booster injections are usually required to ensure lasting immunity. Corynebacterium pseudotuberculosis recombinant protein vaccines have problems such as complex preparation processes, poor stability of recombinant protein antigens, and difficulty in preservation. It is usually necessary to compare and select epitopes with strong immunogenicity, suitable expression systems, and suitable recombinant protein antigen stabilizers.
[0007] Inactivated bacterial vaccines require the cultivation of a large number of bacteria (usually up to 5.0×10 9 CFU / mL), and an inactivator needs to be added for inactivation, and immunization needs to be boosted, so there is a problem of high cost. In addition, the inactivated bacterial vaccine has a weak ability to induce cellular immune response, so the immune protection effect is limited. Summary of the invention
[0008] The purpose of the present invention is to provide a gene-deficient strain of Corynebacterium pseudotuberculosis, a vaccine and a preparation method thereof. The vaccine is easy to prepare, low in cost, can effectively stimulate the humoral immunity and cellular immunity level of the immunized animal, and well resists infection by Corynebacterium pseudotuberculosis.
[0009] In order to achieve the above object, the technical solution adopted by the present invention is:
[0010] The gene-deficient strain of Corynebacterium pseudotuberculosis was obtained by using CRISPR / Cas9 gene editing technology, with the Xuanhan strain of Corynebacterium pseudotuberculosis (XH02) as the parent strain, knocking out the copper-zinc superoxide dismutase gene (sodC) of the Xuanhan strain of Corynebacterium pseudotuberculosis (XH02), and obtaining the gene-deficient strain of Corynebacterium pseudotuberculosis XH02ΔsodC, which was classified and named Corynebacterium pseudotuberculosis XH02ΔsodC, and the preservation date was September 2, 2024. It was preserved in the China Center for Type Culture Collection with the preservation number CCTCC M 20241890.
[0011] The present invention also provides the use of the above-mentioned Corynebacterium pseudotuberculosis gene-deficient strain in the preparation of a live vaccine of Corynebacterium pseudotuberculosis.
[0012] The present invention also provides a live vaccine of Corynebacterium pseudotuberculosis, comprising the gene-deficient strain of Corynebacterium pseudotuberculosis and Montanide TM Gel 02 adjuvant.
[0013] The present invention also provides a method for preparing a live vaccine of Corynebacterium pseudotuberculosis, comprising the following steps:
[0014] S1. Inoculate the gene-deficient strain of Corynebacterium pseudotuberculosis described above into a culture medium for cultivation, and add 0.05-0.3% Tween 80;
[0015] S2. Centrifuge the culture, discard the culture supernatant, wash the precipitate with sterile PBS, resuspend the bacteria with PBS, and add Montanide TM Gel 02 adjuvant to adjust the bacterial concentration to 5.0×10 6 -1.0×10 7 CFU / mL, and obtain the live vaccine of Corynebacterium pseudotuberculosis XH02ΔsodC, wherein the adjuvant concentration is 10-15%.
[0016] Preferably, in step S1, the culture medium is any one of brain heart infusion broth, tryptone soy broth and LB broth plus 5% calf serum.
[0017] Preferably, in step S1, the gene-deficient strain of Corynebacterium pseudotuberculosis is inoculated in a culture medium for culturing, which specifically comprises the following steps: the culture is cultured at 37° C. and 200 rpm for 24 hours.
[0018] The XH02ΔsodC attenuated strain of the present invention is simple to culture and convenient to prepare. It only needs to culture XH02ΔsodC, add a suitable adjuvant and PBS and vortex mix, which is suitable for large-scale production. In addition, the amount of XH02ΔsodC inoculation antigen is low (less than one percent of the inactivated bacterial vaccine antigen), the number of times is small (only one inoculation is required), so the price is relatively low, and it can effectively stimulate the humoral immunity and cellular immunity level of the immunized animal, and resist the infection of Corynebacterium pseudotuberculosis very well. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 This is the construction of pEC-sodCgRNA-HDarm plasmid and the sodC knockout pattern diagram;
[0020] Figure 2 This is the identification result of sodC knockout strain;
[0021] Figure 3 A is the survival rate of mice infected with XH02ΔsodC and XH02; B is the bacterial load of Corynebacterium pseudotuberculosis in the liver of mice infected with XH02ΔsodC and XH02; C is the bacterial load of Corynebacterium pseudotuberculosis in the spleen of mice infected with XH02ΔsodC and XH02; D is the bacterial load of Corynebacterium pseudotuberculosis in the kidney of mice infected with XH02ΔsodC and XH02, ***P<0.001;
[0022] Figure 4A is the result of CD4+ and CD8+ T cell detection in spleen of mice immunized with XH02ΔsodC; B is the ratio of CD4+ / CD8+ T cells in spleen of mice immunized with XH02ΔsodC; C is the level of anti-pseudomonas IgG in serum of mice immunized with XH02ΔsodC; D is the survival curve of mice immunized with XH02ΔsodC against intraperitoneal challenge with XH02, where *P<0.05; **P<0.01; ***P<0.001;
[0023] Figure 5 A is the survival curve of mice immunized with XH02ΔsodC after intraperitoneal challenge with Corynebacterium pseudotuberculosis WZ strain; B is the survival curve of mice immunized with XH02ΔsodC after intraperitoneal challenge with Corynebacterium pseudotuberculosis ZX strain; C is the survival curve of mice immunized with XH02ΔsodC after intraperitoneal challenge with Corynebacterium pseudotuberculosis RC strain. DETAILED DESCRIPTION
[0024] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments.
[0025] 1. Construction process of sodC gene deletion strain of Corynebacterium pseudotuberculosis
[0026] 1. Design PCR primers
[0027] According to the sodC (CP019769.1) sequence published in GenBank, primers were designed using Snapgene software (Table 1) and sent to Beijing Ruiboxing Biotechnology Co., Ltd. for synthesis.
[0028] Table 1 Primers used to construct sodC knockout strains
[0029]
[0030] Note: “——” represents the restriction site; Stands for spacer.
[0031] 2. Construction of pEC-sodCgRNA plasmid
[0032] The sodC Spacer was designed through the website http: / / crispor.tefor.net / , and the 20bp sequence of the Spacer was added to the 5′ end of the primer sodCgRNA-F together with the Eco RI restriction site. Using the plasmid pCas9gRNA-ccdB as a template, sodCgRNA-F and gRNA-R (with a Sal I restriction site at the 5′ end) as primers, sodCgRNA was amplified using PrimerStar, and the PCR product was identified and recovered by gel electrophoresis. The sodCgRNA and pECXK99E were double-digested with EcoR I and Sal I, and the sodCgRNA and pECXK99E plasmids after restriction digestion were ligated with a DNA Ligation Kit. The ligation product was chemically transformed into E. coli DH5α competent cells, and the plasmid was extracted and identified with pECJD-F / R. The constructed plasmid was named pEC-sodCgRNA (such as Figure 1 ).
[0033] 3. Construction of pEC-sodCgRNA-HDarm plasmid
[0034] Using XH02 genome as template, sodCLF / R, sodCRF / R as primers, Primer Star was used to amplify the upstream and downstream homology arms of sodC. Using pEC-sodCgRNA as template, sodCF / R as primers to amplify fragment 1, electrophoresis identification and recovery of products, sodC upstream and downstream homology arms were amplified and connected by Overlap PCR using sodCLF and sodCRR as primers, as homology repair DNA templates, PCR products were identified and recovered by electrophoresis, and fragment 1 and homology repair DNA templates were connected using seamless cloning kits. The ligation product was chemically transformed into Trans1-T-1 competent cells, and the constructed plasmid was named pEC-sodCgRNA-HDarm.
[0035] 4. sodC gene knockout and verification
[0036] pCas9gRNA-ccdB was electrotransformed into XH02 competent cells, spread on LB blood agar plates containing chloramphenicol, and then competent cells containing pCas9gRNA-ccdB were prepared (chloramphenicol was added to the shake culture, with a final concentration of 20 mg / L). pEC-sodCgRNA-HDarm was electrotransformed into competent cells with pCas9gRNA-ccdB, spread on LB blood agar plates containing chloramphenicol, kanamycin and 0.05mM IPTG, and cultured at 37°C for 48h. Monoclonal clones were identified using primers sodCJD-F and sodCJD-R, and their PCR products were sent to Beijing Qingke Biotechnology Co., Ltd. for sequencing verification ( Figure 1 and Figure 2 ),in Figure 2 M is a 5000 bp DNA marker; 1 is XH02; 2 is XH02ΔsodC.
[0037] 5. Elimination of plasmids
[0038] The correctly identified sodC knockout strain was inoculated into LB broth and cultured in a shaking incubator at 37°C. After 5 days of subculture, it was spread on chloramphenicol and kanamycin plates, respectively. If it was sensitive to chloramphenicol and kanamycin, pCas9gRNA-ccdB and pECsodCgRNA-HDarm had been eliminated.
[0039] 2. Preparation method of live vaccine of Corynebacterium pseudotuberculosis
[0040] S1. XH02ΔsodC was cultured in brain heart infusion broth (BHI) or tryptone soy broth (TSB), or LB broth plus 5% calf serum, and 0.1% Tween 80 was added. The culture was cultured at 37°C with constant temperature shaking at 200 rpm for 24 h.
[0041] S2. The culture was centrifuged at 10 000 g for 1 min, the culture supernatant was discarded, the precipitate was washed three times with sterile PBS, the bacteria were resuspended with PBS, and Montanide TM Gel 02 adjuvant (Seppic, France) was added to adjust the bacterial concentration to 5.0×10 6 -1.0×10 7 CFU / mL, and the adjuvant concentration is 10-15%, then the live vaccine of Corynebacterium pseudotuberculosis XH02ΔsodC is prepared.
[0042] 3. Immunization method of Corynebacterium pseudotuberculosis XH02ΔsodC live vaccine: multiple (2-4 points) subcutaneous injection or intramuscular injection is used to immunize the recipient animals.
[0043] IV. Pathogenicity experiment of Corynebacterium pseudotuberculosis XH02ΔsodC
[0044] Kunming mice (1.6×10 7 CFU / 0.2mL / mouse) and observed for 14 days to determine the pathogenicity of XH02ΔsodC to mice. In addition, Kunming mice (1.6×10 7 CFU / 0.2mL / mouse). At 72h after infection, the liver, spleen and kidney of the mice were collected aseptically, added with 2mL of sterile PBS solution for homogenization, and the bacterial load of each organ was calculated using the standard plate count method.
[0045] Figure 3 The pathogenicity and organ bacterial load of mice infected with XH02ΔsodC and XH02, ***P<0.001, the results showed that compared with mice infected with XH02, the mortality rate of mice infected with XH02ΔsodC was significantly reduced ( Figure 3 A), the bacterial load of Corynebacterium pseudotuberculosis in the organs of mice infected with XH02ΔsodC was significantly reduced, with the reduction rates of bacteria in the liver, spleen and kidney being 99.76%, 99.07% and 99.61% respectively ( Figure 3 BD).
[0046] V. Evaluation test of immune protection of live vaccine against Corynebacterium pseudotuberculosis XH02ΔsodC
[0047] (I) Evaluation of protection of live vaccine against parent strain of Corynebacterium pseudotuberculosis XH02ΔsodC
[0048] Seventy-six Kunming mice (male, 6-8 weeks old) were randomly divided into 4 groups, 19 mice in each group:
[0049] Mice in group G1 (PBS control) were injected with 0.4 mL PBS;
[0050] Mice in group G2 (adjuvant control) were injected with 0.4 mL 10% Montanide TM Gel 02;
[0051] The G3 and G4 groups were immunized with XH02ΔsodC attenuated live vaccine (XH02ΔsodC attenuated live vaccine containing 10% Montanide TM Gel 02 adjuvant, and the immunization dose of mice in the G3 group was 1×10 6 CFU / 0.4mL / mouse, the immunization dose for mice in group G4 was 4.0×10 6 CFU / 0.4mL / mouse), and the immunization method was multiple injections subcutaneously at the back.
[0052] (1) Antibody detection: 30 days after immunization, four mice were randomly selected to collect eye blood and separate serum. IgG levels were measured by indirect ELISA. XH02 (1.0×10 9 CFU / mL) as antigen and coated overnight at 4°C. After washing three times with PBST, the wells were blocked with 3% BSA at 37°C for 2h. Washed three times again and incubated with serum samples (1:128 dilution) at 37°C for 0.5h, then washed three times with PBST. HRP-conjugated anti-mouse total IgG antibody (1:1000 dilution) was incubated at 37°C for 0.5h. After washing three times with PBST, TMB colorimetric solution was added for color development for 10min and the reaction was terminated with dilute sulfuric acid. OD was detected by microplate reader 450 value.
[0053] (2) CD4 + 、CD8 + T cell analysis: 30 days after immunization, four mice were randomly selected, spleens were removed aseptically, and spleen cells were prepared. Splenocytes were diluted to 1×10 6 Cells were incubated on ice for 30 min in the dark with mouse anti-CD3-FITC, CD4-APC and CD8-PE flow cytometry antibodies. After incubation, 1 mL of PBS was added to each sample, which was then centrifuged at 2000 rpm for 10 min and washed twice with PBS. The cells were resuspended in 500 μL PBS and analyzed by flow cytometry for CD4 + and CD8 + T lymphocyte count and calculation of CD4 + / CD8 + T cell ratio.
[0054] (3) Evaluation of immune protection: 30 days after immunization, the subjects were intraperitoneally challenged with XH02 (4.0×10 7 CFU / 0.4mL / mouse), and monitored the survival of mice within 14 days, drew the survival curve, and calculated the immune protection rate.
[0055] Figure 4 CD4 in spleen of mice immunized with XH02ΔsodC + 、CD8 + T cells, serum IgG levels and protection against XH02 challenge, *P<0.05; **P<0.01; ***P<0.001. The results showed that compared with the mice in the PBS control group, XH02ΔsodC immunization led to a decrease in CD4 + T cells increased significantly, CD8 + A significant decrease in T cells ( Figure 4 A) CD4 in spleen cells of XH02ΔsodC immunized mice + / CD8 + The ratio increased significantly ( Figure 4 B). The level of anti-Corynebacterium pseudotuberculosis IgG in the serum of mice immunized with XH02ΔsodC was significantly higher than that of mice in the PBS control group ( Figure 4 C). In addition, more mice in the G1 and G2 groups began to die on the 3rd day after the XH02 challenge, and by the 10th day, all mice in these two groups had died. Only one mouse died in the G3 group on the 5th and 6th day after the challenge. No mice in the G4 group died. The protection rate of mice immunized with XH02ΔsodC against the XH02 challenge was 81.81% (G3 group, immunization dose was 1.0×10 6 CFU / mouse) and 100% (G4 group, immunization dose was 4.0×10 6CFU / mouse) ( Figure 4 D).
[0056] (II) Evaluation of cross-protection of XH02ΔsodC live vaccine against other strains
[0057] Forty-eight Kunming mice (male, 6-8 weeks old) were randomly divided into six groups, with eight mice in each group. Three of the groups were immunized subcutaneously with XH02ΔsodC attenuated live vaccine (immunization dose was 4.0×10 6 CFU / 0.4mL / mouse), and the other three groups of mice were Montanide TM Gel adjuvant control groups (each mouse was subcutaneously injected with 0.4mL 10% Montanide TM Gel 02). After 14 days of immunization, the mice were challenged with different clinical isolates of Corynebacterium pseudotuberculosis: Wanzhou strain (WZ, challenge dose was 2.0×10 6 CFU / 0.2mL / mouse), Zhongxian strain (ZX, challenge dose was 2.0×10 6 CFU / 0.2mL / mouse) and Rongchang strain (RC, challenge dose was 1.6×10 7 CFU / 0.2mL / mouse). The survival of mice was monitored continuously for 14 days.
[0058] Figure 5 The cross-protection effect of XH02ΔsodC-immunized mice against different clinical isolates of Corynebacterium pseudotuberculosis was shown in Figure 1. The protection rate of XH02ΔsodC-immunized mice against Corynebacterium pseudotuberculosis WZ strain was 100% ( Figure 5 A), the protection rate against the challenge of Corynebacterium pseudotuberculosis ZX strain was 100% ( Figure 5 B), the protection rate against the challenge of Corynebacterium pseudotuberculosis RC strain reached 87.5% ( Figure 5 C). These results indicate that XH02ΔsodC has good cross-protection against different isolates of Corynebacterium pseudotuberculosis.
Claims
1. A gene-deficient strain of Corynebacterium pseudotuberculosis, It is characterized in that The gene-deficient strain of Corynebacterium pseudotuberculosis is XH02ΔsodC, and its deposit number is CCTCC M 20241890.
2. A method for constructing a gene-deficient strain of Corynebacterium pseudotuberculosis, It is characterized in that include: The sodC gene of the parent strain of Corynebacterium pseudotuberculosis was knocked out using CRISPR / Cas9 gene editing technology to obtain a gene-deficient strain of Corynebacterium pseudotuberculosis.
3. Use of the gene-deficient strain of Corynebacterium pseudotuberculosis according to claim 1 in the preparation of a live vaccine of Corynebacterium pseudotuberculosis.
4. A live vaccine of Corynebacterium pseudotuberculosis, It is characterized in that The invention comprises the gene-deficient strain of Corynebacterium pseudotuberculosis according to claim 1 or 2 and Montanide TM Gel 02 adjuvant.
5. A method for preparing a live vaccine of Corynebacterium pseudotuberculosis, It is characterized in that The following steps are involved: S1. Inoculate the gene-deficient strain of Corynebacterium pseudotuberculosis according to claim 1 or 2 into a culture medium for culture, and add 0.05-0.3% Tween 80; S2. Centrifuge the culture, discard the culture supernatant, wash the precipitate with sterile PBS, resuspend the bacteria with PBS, and add Montanide TM Gel 02 adjuvant to adjust the bacterial concentration to 5.0×10 6 -1.0×10 7 CFU / mL, and obtain the live vaccine of Corynebacterium pseudotuberculosis XH02ΔsodC, wherein the adjuvant concentration is 10-15%.
6. The preparation method according to claim 5, It is characterized in that In step S1, the culture medium is any one of brain heart infusion broth, tryptone soy broth and LB broth plus 5% calf serum.
7. The preparation method according to claim 5 or 6, It is characterized in that In step S1, the gene-deficient strain of Corynebacterium pseudotuberculosis is inoculated in a culture medium for culture, which specifically includes the following steps: the culture is cultured at 37° C. and 200 rpm for 24 hours.
